公开(公告)号：EP3366676A1

公开(公告)日：2018-08-29

申请号：EP15906444.3

申请日：2015-10-20

申请人： Zhejiang Hisun Pharmaceutical Co., Ltd

发明人： XU, Jinyi ,  ZHANG, Liang ,  ZHANG, Xiangyang ,  WANG, Xinzeng ,  CHAI, Jian ,  LUO, Hongying ,  YANG, Zhiqing

IPC分类号： C07D215/227

CPC分类号： C07D215/227 ,  A61P31/06 ,  B01D9/0063

摘要： Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines.

公开(公告)号：EP3115360A1

公开(公告)日：2017-01-11

申请号：EP15759282.5

申请日：2015-03-04

申请人： Zhejiang Hisun Pharmaceutical Co. Ltd.

发明人： ZHANG, Liang ,  LIU, Chuan ,  XU, Jinyi ,  ZHANG, Zhaozhao ,  CHEN, Zhi ,  CHAI, Jian ,  YANG, Zhiqing ,  LUO, Hairong ,  ZHANG, Xiangyang

IPC分类号： C07D401/12 ,  C07C303/44 ,  C07C309/04 ,  A61K31/4439 ,  A61P7/02

CPC分类号： C07D401/12 ,  C07B2200/13 ,  C07C303/44 ,  C07C309/04 ,  C07D403/12

摘要： The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2θ diffraction angles: 5.7±0.2°, 6.2±0.2°, 11.2±0.2°, 12.4±0.2°, 18.2±0.2°, 21.4±0.2°, 21.8±0.2° and 23.6±0.2°; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2θ diffraction angles: 6.0±0.2°, 11.8±0.2°, 18.2±0.2°, 21.6±0.2°, 24.4±0.2°, 27.7±0.2° and 29.7±0.2°. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.

摘要翻译： 本发明涉及甲磺酸达比加群酯的新型结晶形式M和N及其制备方法和用途，其中晶型M的X射线粉末衍射图在以下2θ衍射角为5.7±0.2°处具有特征峰， 6.2±0.2°，11.2±0.2°，12.4±0.2°，18.2±0.2°，21.4±0.2°，21.8±0.2°和23.6±0.2°; 晶体形式N的X射线粉末衍射图在以下2θ衍射角处具有特征峰：6.0±0.2°，11.8±0.2°，18.2±0.2°，21.6±0.2°，24.4±0.2°，27.7± 0.2°和29.7±0.2°。 本发明的结晶形式在浸出时间，生物释放，化学稳定性和加工适应性方面具有优异的性能。

公开(公告)号：EP3342778A1

公开(公告)日：2018-07-04

申请号：EP16840785.6

申请日：2016-08-26

申请人： Zhejiang Hisun Pharmaceutical Co., Ltd.

发明人： YANG, Zhiqing ,  ZHANG, Liang ,  ZHANG, Xiangyang ,  SHI, Zhenjuan ,  SU, Di ,  LUO, Hairong ,  LUO, Hongying ,  FU, Dejin

IPC分类号： C07H19/20 ,  C07H19/16 ,  C07H1/06 ,  A61P35/00

CPC分类号： C07H19/20 ,  C07B2200/13 ,  C07H1/06 ,  C07H19/16

摘要： Provided are a new crystal form of fludarabine phosphate, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the fludarabine phosphate have excellent properties in terms of solubleness, dissolution rate, chemical stability, and processing adaptability.